Discussion
CRS is a heterogeneous disease, with at least two main clinical
phenotypes (CRSwNP and CRSsNP), and it is characterized by a complex
interaction between the degree of upper airway inflammation (mainly
Type-2) and its clinical expression; genetic, environmental and
behavioral factors, together with the presence of relevant
comorbidities, contribute to determine the degree of disease severity
(i.e.: recurrence rate after surgery, the need of systemic
corticosteroid treatment…) and the its impact on patient’s QoL
and health-care related costs (Figure 2). For all these reasons, a more
personalized approach, including a more precise disease endotypization,
should be implemented in caring patients with CRS. In order to achieve
this aim, a multidisciplinary team, including at least
otolaryngologists, allegists/clinical immunologists, pulmunologists and
phycologists, is mandatory (Figure 1), particularly in a era in which
novel therapeutical approaches, such as biologic agents and innovative
surgical treatments (i.e.: the so-called “reboot surgery”) face the
scenario of CRS management.